Three-component research blend containing GHK-Cu, BPC-157 and TB-500, supplied as a lyophilised vial.
GLOW combines three separate research peptides: GHK-Cu, BPC-157 and TB-500. It is studied in controlled laboratory and preclinical models involving extracellular-matrix signalling, cellular migration, angiogenic responses and tissue-related pathways. The combined blend has not been clinically evaluated. For laboratory research only. Not for human or veterinary use.
The following information is provided for research-catalogue and product specification purposes only. Batch-specific identity, purity, salt form and analytical values should be confirmed against the relevant Certificate of Analysis.
| What it is | GLOW combines three separate research peptides: GHK-Cu, BPC-157 and TB-500. It is studied in controlled laboratory and preclinical models involving extracellular-matrix signalling, cellular migration, angiogenic responses and tissue-related pathways. The combined blend has not been clinically evaluated. For laboratory research only. Not for human or veterinary use. |
|---|---|
| Sequence | GHK-Cu: Gly-His-Lys·Cu(II) BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser |
| Molecular weight | GHK-Cu: 401.91 g/mol; BPC-157: 1419.5 g/mol; TB-500: 4963 g/mol |
| Product family | Multi-Peptide Research Blends |
| Research classification | Three-peptide blend / Tissue and extracellular-matrix signalling research |
| Form | Lyophilised three-peptide blend |
| Appearance | Blue to blue-green lyophilised powder |
| Fill quantity | 70mg |
| Container type | Sealed glass vial |
| Storage | Store at 2–8°C for short-term storage or at −20°C for long-term storage. Protect from light and moisture. Avoid repeated freeze-thaw cycles and refer to the batch-specific Certificate of Analysis. |
| Synonyms | GLOW; GHK-Cu/BPC-157/TB-500 blend; three-peptide research blend |
| CAS number | GHK-Cu: 89030-95-5; BPC-157: 137525-51-0; TB-500: 77591-33-4 |
| Molecular form / formula | GHK-Cu: C14H22CuN6O4; BPC-157: C62H98N16O22; TB-500: C212H350N56O78S |
| Molecule form | Three-component lyophilised blend; GHK copper(II) complex; counter-ion according to batch COA |
| Purity | ≥99% per component (HPLC; batch-specific COA) |
| Analysis method | HPLC and mass spectrometry (MS) |
Each compound is accompanied by third-party analytical documentation where available. Certificates confirm purity, identity and chromatographic analysis against the supplied batch.
Orders confirmed early in the day are dispatched the same day; otherwise within 1–2 business days of confirmed payment. After dispatch, delivery within Kenya ($5) is same-day in and around Nairobi and up to 2 days anywhere else in Kenya, while delivery to the rest of Africa ($30) takes around 5 days. All shipping is tracked and discreetly packaged.
Store at 2–8°C for short-term storage or at −20°C for long-term storage. Protect from light and moisture. Avoid repeated freeze-thaw cycles and refer to the batch-specific Certificate of Analysis.
| Form | Lyophilised three-peptide blend |
|---|---|
| Appearance | Blue to blue-green lyophilised powder |
| Container type | Sealed glass vial |
| Storage & Handling | Store at 2–8°C for short-term storage or at −20°C for long-term storage. Protect from light and moisture. Avoid repeated freeze-thaw cycles and refer to the batch-specific Certificate of Analysis. |
All products are supplied by Greek Peptides for research use only. They are not licensed as pharmaceuticals and are not promoted as, or intended to diagnose, treat, cure, prevent or mitigate any disease or medical condition in humans or animals. They are not intended for human or animal consumption and are not intended for cosmetic, nutritional or recreational use.
By purchasing, the purchaser confirms that they are a qualified individual acting for legitimate research purposes only and accepts our Terms and Conditions and Research Use Policy.
